Puma Biotechnology, Inc. — FY 2012 Form 10-K
Reporting period: Fiscal year ended December 31, 2012; filed April 1, 2013. Puma was a development-stage oncology biopharmaceutical company with no approved products or product revenue. Its pipeline centered on neratinib (oral and intravenous) and PB357, licensed from Pfizer.
Financial performance and liquidity
| Metric | FY 2012 | FY 2011 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $49.6 million | $0.8 million |
| General and administrative expense | $24.8 million | $9.3 million |
| Operating loss | $74.5 million | $10.2 million |
| Net loss | $74.4 million | $10.2 million |
| Basic and diluted loss per share | $3.42 | $1.32 |
| Cash used in operating activities | $44.0 million | $1.8 million |
At year-end, cash and cash equivalents were $137.4 million, current assets were $149.0 million, and current liabilities were $21.7 million. Total liabilities were $22.8 million, including $21.2 million of accrued expenses; no borrowings are listed on the balance sheet. Cash provided by financing activities was $129.3 million, principally from the October 2012 stock offering, which generated $129.2 million net proceeds. The filing reports no product gross margin; margin metrics are not meaningful without product sales.
FY 2012 net loss included $18.2 million of incremental non-cash compensation expense from revaluing the CEO’s anti-dilutive warrant. Management’s non-GAAP presentation, which also removes stock compensation and specified legacy-trial costs, reported a $16.8 million adjusted net loss; this is a company-defined measure, not a substitute for GAAP results.
Material changes and unusual items
- R&D spending rose sharply as Puma assumed clinical-trial responsibilities from Pfizer and expanded development activities. The company attributed approximately $5.1 million of 2012 R&D expense to duplicated transition work.
- Under the Pfizer cost cap for inherited trials, Puma recorded a $10.6 million licensor receivable for excess external trial costs. Accrued CRO/licensor services were $19.8 million at year-end.
- FY 2011 is not a directly comparable operating baseline: the company was newly operating after the 2011 merger and was still building its infrastructure.
- The October 2012 public offering increased outstanding shares to 28.7 million at year-end. Puma reported no cash dividends and no off-balance-sheet arrangements.
Outlook, risks and contingencies
- Management estimated 12-month R&D spending of $40–$45 million and G&A spending of $6–$7 million, both excluding stock-based compensation. It believed year-end cash could fund operations through 2014 and into 2015, while noting assumptions could prove wrong and further financing might be needed.
- The company anticipated beginning a roughly 600-patient Phase III trial of oral neratinib plus capecitabine versus lapatinib plus capecitabine in third-line HER2-positive metastatic breast cancer in Q2 2013. The FDA had agreed to the protocol under a Special Protocol Assessment; the filing cautions this does not assure trial success or approval.
- Management expected continued operating losses and negative operating cash flow. Development, recruitment, safety, regulatory review, manufacturing, third-party CRO execution, competition, reimbursement, financing and dependence on Pfizer-licensed intellectual property are material risks.
- The Pfizer license provides for up to $187.5 million in milestone payments if all milestones are achieved and royalties of approximately 10%–20% of net sales if products are commercialized. These are contingent obligations, not current debt.
- Management estimated product approval could be as early as approximately 2015, assuming no unforeseen safety issues. This was an expectation, not assured guidance. The filing also disclosed CRO agreements of up to $25.7 million for legacy trials and subsequent 2013 agreements of up to $22.6 million for the planned Phase III trial and $4.1 million for a Phase II lung-cancer trial.
Most important facts for investors to verify
- Current cash, operating burn and whether financing is required sooner than management’s estimated runway.
- Progress, enrollment, outcomes and regulatory implications of the planned Phase III trial and ongoing Phase II programs.
- Collection and timing of the $10.6 million Pfizer receivable, and the final costs of inherited clinical trials.
- The effect of the CEO warrant and future equity awards on dilution; the warrant covers 2,116,250 shares at $16 per share through October 2021.
- Future obligations under the Pfizer license, CRO contracts and office leases, as well as the likelihood and timing of milestone payments and royalties.